These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17105431)

  • 21. Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization.
    Gandhi S; Refolo LM; Sambamurti K
    J Mol Neurosci; 2004; 24(1):137-43. PubMed ID: 15314262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures.
    Gasparini L; Rusconi L; Xu H; del Soldato P; Ongini E
    J Neurochem; 2004 Jan; 88(2):337-48. PubMed ID: 14690522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012.
    Pettersson M; Stepan AF; Kauffman GW; Johnson DS
    Expert Opin Ther Pat; 2013 Oct; 23(10):1349-66. PubMed ID: 23875696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors.
    Close J; Heidebrecht R; Hendrix J; Li C; Munoz B; Surdi L; Kattar S; Tempest P; Moses P; Geng X; Hughes B; Smotrov N; Moxham C; Chapnick J; Kariv I; Nikov G; Burke JE; Deshmukh S; Jeliazkova-Mecheva V; Leach JK; Diaz D; Xu L; Yang Z; Kwei G; Moy L; Shah S; Tanga F; Kenefic C; Savage D; Shearman M; Ball RG; McNevin MJ; Markarewicz A; Miller T
    Bioorg Med Chem Lett; 2012 May; 22(9):3203-7. PubMed ID: 22483609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Aβ42 prompted by exogenous fibrillary or soluble Aβ25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease.
    Armato U; Chiarini A; Chakravarthy B; Chioffi F; Pacchiana R; Colarusso E; Whitfield JF; Dal Prà I
    Biochim Biophys Acta; 2013 Oct; 1832(10):1634-52. PubMed ID: 23628734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease.
    Imbimbo BP
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1147-68. PubMed ID: 19589092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological and Toxicological Properties of the Potent Oral
    Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE
    J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi.
    Xia W; Zhang J; Ostaszewski BL; Kimberly WT; Seubert P; Koo EH; Shen J; Selkoe DJ
    Biochemistry; 1998 Nov; 37(47):16465-71. PubMed ID: 9843412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.
    Beher D; Clarke EE; Wrigley JD; Martin AC; Nadin A; Churcher I; Shearman MS
    J Biol Chem; 2004 Oct; 279(42):43419-26. PubMed ID: 15304503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel γ-secretase modulators: a review of patents from 2008 to 2010.
    Pettersson M; Kauffman GW; am Ende CW; Patel NC; Stiff C; Tran TP; Johnson DS
    Expert Opin Ther Pat; 2011 Feb; 21(2):205-26. PubMed ID: 21231889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage.
    Teranishi Y; Inoue M; Yamamoto NG; Kihara T; Wiehager B; Ishikawa T; Winblad B; Schedin-Weiss S; Frykman S; Tjernberg LO
    FEBS J; 2015 Sep; 282(17):3438-51. PubMed ID: 26094765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
    Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
    Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective amyloid-beta lowering agents.
    Wolfe MS
    BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S4. PubMed ID: 19090992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gnetin C, a resveratrol dimer, reduces amyloid-β 1-42 (Aβ42) production and ameliorates Aβ42-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells.
    Seino S; Kimoto T; Yoshida H; Tanji K; Matsumiya T; Hayakari R; Seya K; Kawaguchi S; Tsuruga K; Tanaka H; Imaizumi T
    Biomed Res; 2018; 39(3):105-115. PubMed ID: 29899186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease.
    Hillmann A; Hahn S; Schilling S; Hoffmann T; Demuth HU; Bulic B; Schneider-Axmann T; Bayer TA; Weggen S; Wirths O
    Neurobiol Aging; 2012 Apr; 33(4):833.e39-50. PubMed ID: 21943956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design.
    Moore CL; Leatherwood DD; Diehl TS; Selkoe DJ; Wolfe MS
    J Med Chem; 2000 Sep; 43(18):3434-42. PubMed ID: 10978191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.